Jazz Pharmaceuticals wins approval for HSE reimbursement of cannabis-derived drug

The company acquired GW Pharma, the UK biopharma and producer of cannabis-derived Epidiolex, earlier this year

Jazz Pharmaceuticals acquired GW Pharma, a producer of cannabis-derived medicines, in May 2021 in a cash-and-stock deal worth $7.2 billion (€6.3 billion). Picture: Getty